Subpotent Antibiotic Recalled

Lupin Pharmaceuticals Inc is recalling 3138 bottles of cefixime for oral suspension because of subpotency, according to the May 26, 2021, US Food and Drug Administration (FDA) Enforcement Report. 

The recall affects cefixime for oral suspension, 100 mg/5mL, in 50-mL HDPE bottles, from lot F900787 (Exp. 4/21). The medication was manufactured by Lupin Limited, Mandideep, India, and Lupin Pharmaceuticals Inc., Baltimore, MD, the FDA reported, and distributed throughout the United States.   

Lupin Pharmaceuticals voluntarily initiated the recall April 29, 2021. On May 19, 2021, the FDA designated the recall Class II. Drugs affected by Class II recalls may cause temporary or medically reversible adverse health consequences if used. While remote, a possibility of serious harm also exists. 

Cefixime for oral suspension is a prescription antibiotic used to treat a variety of bacterial infections, including uncomplicated urinary tract infections, otitis media, and pharyngitis and tonsillitis.